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Stent thrombosisa b s t r a c t
Background: The biolimus-eluting stent (BES) was the first to elute anti-proliferative drug from a
biodegradable polymer. In the randomized LEADERS trial, a stainless steel BES showed non-inferior effi-
cacy compared to a sirolimus-eluting stent and a long-term safety advantage. We report the first clinical
efficacy and safety outcomes of a new thin-strut cobalt chromium biolimus-eluting stent (CoCr-BES) from
an international multi-centre registry.
Methods: We studied 400 all-comer patients with coronary disease receiving CoCr-BES at 12 centres,
with follow-up at 9 months and 2 years. The primary endpoint was incidence of major adverse cardiac
events (MACE) at 9 months comprising cardiac death, myocardial infarction (MI), and clinically indicated
target vessel revascularization (ci-TVR). Key protocol elements were the same as the randomized
LEADERS trial to enable a historical control for propensity-matched comparison.
Results: Mean patient age was 65 ± 11 years, 19% had diabetes, and 55% presented with unstable angina
or MI. On discharge, 96% of patients were on dual antiplatelet therapy (DAPT) and 69% were on DAPT at
9 months. MACE at 9 months occurred in 3.9% of patients, cardiac death in 0.8%, MI in 1.1% and ci-TVR in
2.7%. One patient (0.25%) experienced definite or probable stent thrombosis (ST). A propensity-adjusted
comparison showed similar clinical outcomes to the BES arm in the LEADERS trial for the primary end-
point MACE.
Conclusions: The new CoCr-BES showed low rates of MACE, MI, ci-TVR and ST at 9 months, similar to the
BES arm in LEADERS.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug-eluting stents (DES) constitute the current standard of
care for acute and elective patients undergoing percutaneous coro-nary intervention [1–3]. While first-generation DES typically used
durable polymers to store and modulate the release of the anti-
proliferative drug, later generations have introduced biodegrad-
able polymers with the intent to reduce untoward side effects
occurring as an intolerance or hypersensitivity reaction of the ves-
sel wall to the polymer. One of these 2nd generation DES, the
Biolimus-eluting stent (BES) (Biomatrix FlexTM, Biosensors Interna-
tional, Morges, Switzerland), released the drug Biolimus-A9 from a
biodegradable polymer [4]. The BES was compared head-to-head
with the first Sirolimus-eluting stent (SES) (CypherTM, Cordis, Miami
Lakes, FL, USA) in the LEADERS trial. In this comparative study, the
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a safety improvement with less very late stent thrombosis events
from 3 to 5 years - an advantage that was attributed to the
biodegradable polymer [6,7].
Recently, an iteration of the BES was developed based on a CoCr
thin-strut platform (83 um strut thickness), while all other design
elements of the BES including the BA-9 drug, the drug dose, the PLA
polymer and the drug release kinetics were kept the same. Accord-
ing to its similarity with the BES, the new CoCr-BES (Biomatrix
AlphaTM, Biosensors International, Morges, Switzerland) received
CE-mark approval in 2015 through a regulatory pathway that does
not require a new clinical trial.
The present study was designed as a post-market surveillance
registry to evaluate the clinical safety and effectiveness data of
the CoCr-BES stent in day-to-day clinical use. Key design elements
of the registry protocol were kept the same as in the LEADERS trial
so that it was possible to use the BES arm of the LEADERS study [5]
as a historic reference in a propensity-matched comparison.2. Methods
2.1. New CoCr-Biolimus-eluting stent design
The CoCr-BES evaluated in this registry is abluminally coated
with a mixture of the Biolimus-A9 drug and a PLA polymer matrix
(50:50 by weight) in a dose of 15.6 mg/mm stent length. Biolimus-
A9 is a Sirolimus derivative that has the same ring structure as Sir-
olimus, but a ligand modification that results in a 10-fold increased
lipophilicity. Biolimus-A9 is an m-TOR inhibitor with a cytostatic
mechanism of action that has close similarity to Sirolimus. The
polymer is a biodegradable poly-lactic acid (PLA) which is
absorbed within 6–9 months. While drug and polymer are identi-
cal to the BES in formulation and dose, the new CoCr-BES uses a
cobalt-chromium (MP35N) rather than stainless steel (316L) stent
platform enabling a reduction of stent strut thickness from 120 mm
to 83 mm while maintaining a similar radial strength. All other
stent design elements have remained unchanged including the
stent platforms hybrid design of mid-section S-connectors for
improved flexibility combined with straight connectors for higher
longitudinal strength in the proximal and distal end sections of
the stent (Fig. 1).2.2. Study design and patients
The Biomatrix AlphaTM Registry was a prospective, single-arm,
multi-centre post-market registry designed to enroll 400 patients
with stable coronary artery disease or acute coronary syndromes,
similar to the patients recruited into the LEADERS study. The reg-
istry was conducted in 12 centres in 4 countries in Europe and Asia.
Patients were enrolled between October 2016 and October 2017.
The registry was managed by the Cardiovascular European
Research Center (CERC) in Massy, France.
Although not formally consecutive, an ‘‘all-comer” patient pop-
ulation was sought. Thus, patients were eligible for inclusion into
the registry if they had undergone PCI in one or more coronary
arteries or coronary bypass grafts with one or more CoCr-BES.
There were no limitations as to the number of treated vessels, or
the number, type and length of treated lesions. Patients were
excluded if any additional stent(s) different from the study stent
were implanted during the index procedure. There were no exclu-
sion criteria related to clinical presentation. Dual antiplatelet ther-
apy (DAPT) with aspirin and a P2Y12 inhibitor was recommended as
per clinical practice guidelines.
The study complied with the declaration of Helsinki and was
approved by institutional ethics committees where applicable. Allpatients provided written informed consent for participation in
the registry and were followed at 30 days and 9 months. The
2 years follow-up data collection is still ongoing at this point in
time.
The primary endpoint was the incidence of major adverse car-
diac events (MACE) at 9 months - a composite of cardiac death,
myocardial infarction (MI) and clinically-indicated target vessel
revascularization (ci-TVR). Pre-defined secondary endpoints
included, among others, ARC definite/probable stent thrombosis
(ST), the individual components of the primary endpoint, target
lesion failure (TLF) – a composite of cardiac death, target-vessel
MI or clinically-indicated target lesion revascularization, and the
patient oriented composite endpoint (POCE) - a composite of all-
cause mortality, MI, or any ciTVR.2.3. Data and definitions
The study was conducted in accordance with GCP guidelines
and the 1975 Declaration of Helsinki. Informed consent from each
patient was obtained before data collection. Baseline data included
demographic information, medical history, cardiovascular risk fac-
tors, lesion and procedure details and antithrombotic medications.
Data were collected electronically at each participating centre and
stored in a central database (BePATIENT, Paris, France). All data
were checked for consistency. Electronic queries were issued as
required. All reported MACE and ST events were monitored,
checked against source documents and adjudicated by an indepen-
dent Clinical Event Committee (CEC). Through a risk-based
approach, the rate of overall source document verification was 10%.
Cardiac death was defined as any death due to immediate car-
diac cause (e.g. MI, low-output failure, fatal arrhythmia), unwit-
nessed death and death of unknown cause. Myocardial infarction
was defined through the Third Universal Definition of MI [8]. Ci-
TVR was defined as a repeat PCI or bypass surgery of the target ves-
sel associated with either a  70% vessel diameter reduction or
a  50% diameter reduction in combination with angina and/or
documented ischemia. ST was categorized as definite and/or prob-
able according to the Academic Research Consortium (ARC) defini-
tions [9,10], and all the relevant angiograms were reviewed by the
CEC.2.4. Statistical analysis
2.4.1. Variables
For continuous variables, mean and standard deviation are
reported. For categorical variables, counts and percentages are
shown. The denominator for the calculation of percentages is based
upon the number of non-missing values available, unless
otherwise specified. Clinical events are reported as Kaplan-Meier
estimates with corresponding confidence intervals based on the
log-log transformation and hazard ratio derived from the Cox pro-
portional hazard model. All data were analysed using SAS V.9.4
(SAS Institute, Cary, North Carolina, USA).
The registry was powered to compare the observed MACE rate
to the historical MACE rate of 9.2% as observed in the BES arm of
the LEADERS study at 9 months. Assuming a 9.2% event rate for
the BES, a one-sided type I error (a) of 0.05, and a 4% non-
inferiority margin, a sample size of 400 patients would have more
than 80% power to conclude non-inferiority of the new CoCr-BES
compared with the BES historical control. Non-inferiority would
thus be met if the upper limit of the 90% Wald confidence interval
for the 9 months MACE rate for the CoCr-BES was less than 13.2%
(9.2% + 4%).
Fig. 1. A: Flattened view of the cobalt chromium stent platform (small vessel model) B: Details of the straight and curved link connectors C: Comparison with LEADERS
(historical control), with propensity matching and landmark analysis at day 3 for the primary endpoint of major adverse cardiac events at 9 months.
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landmark analysis
We sought to compare the outcomes of the CoCr-BES in this
registry with the patients in the BES arm in the LEADERS trial,
and selected the 644 patients that that were not scheduled per pro-
tocol for follow-up angiography as a reference group in order to
avoid an artificially elevated repeat revascularization rate [11]. In
order to adjust for potential baseline patient condition discrepan-
cies, we conducted a patient-level propensity score analysis
between the datasets of the CoCr-BES in this registry and the BES
arm of LEADERS. The propensity for each patient was modelled
as the probability of being part of the new registry versus being
part of the BES arm in LEADERS (propensity score), estimating this
probability by logistic regression [12–14] using a pre-specified listof baseline covariates. The full list of baseline variables used in
the propensity score calculation is provided in supplementary
materials (Table S1). Two different propensity methods were used,
including a 5-strata method as well as a propensity inverse proba-
bility weighting (IPW) [13] with KM estimate weighted by each
patient’s inverse propensity score.
Although the CoCr-BES registry protocol was designed to emu-
late the LEADERS protocol, of note the updated Third Universal
Definition of Myocardial Infarction [8] established in 2012 was
used for the registry. Recognizing that the different definitions
might introduce a potential discrepancy in MI reporting between
the registry and the LEADERS trial, particularly for peri-
procedural MI (within 48 h), we conducted for comparison a land-
mark analysis censoring clinical events which were part of the
Table 1
Baseline characteristics of the study population.
Patient characteristics Biomatrix AlphaTM Registry
Population N (%)
Age (years) 64.7 ± 11
Male 314 (78.5%)
BMI (kg/m2) 28.2 ± 5.0
History of gastrointestinal bleeding 9 (2.3%)
History of malignancy 23 (5.8%)
Renal insufficiency 46 (11.5%)
Prior MI 75 (18.8%)
Prior CABG or PCI 98 (24.6%)
Diabetes mellitus 77 (19.3%)
Current smoker 82 (21.0%)
Dyslipidaemia 221 (56.7%)
Arterial hypertension 225 (57.3%)
Family history of coronary artery disease 135 (38.0%)
Stable angina pectoris 134 (33.5%)
Silent ischemia 27 (6.8%)
Unstable angina 56 (14.0%)
ST-segment elevation MI (STEMI) 65 (16.3%)
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of the primary endpoint between the two trials clinically meaning-
ful. An analysis without the day-3 landmark was also done as sen-
sitivity analysis (Table S2 of the supplementary materials)
2.4.3. Comparison with other previous studies and registries of the
stainless steel Biolimus-eluting stent
For additional comparison beyond LEADERS we used two previ-
ous randomized clinical studies and two clinical registries con-
ducted with the BES to help put the outcomes of this new
registry into appropriate perspective. The SORT-OUT VI study com-
pared the BES with the Zotarolimus-eluting stent (Resolute Integ-
rityTM, Medtronic, Minneapolis, MN, USA) in a randomized fashion
[15], and the SORT-OUT VIII trial compared the BES with the
everolimus-eluting stent [16] (SynergyTM, Boston Scientific, Malbor-
ough, MA, USA). The e-BioMatrix Registry included 5,472 patients
in Europe and Middle East and was published in 2015 [17]. The
e-Biomatrix French Registry recruited 2,365 patients and was pub-
lished in 2017 [18].Non-ST-segment elevation MI (NSTEMI) 99 (24.8%)
Ejection fraction (%) 56.6 ± 12.4
Lesions treated 562
Lesions per patient 1.40 ± 0.64
Lesion class
Type A 99 (17.6%)
Type B1 169 (30.1%)
Type B2 144 (25.6%)
Type C 150 (26.7%)
Lesion length 21.7 ± 12.8
Lesion length >30 mm 96 (17.1%)
Reference vessel diameter (RVD) 3.05 ± 0.52
Small vessel (RVD < 2.75 mm) 147 (26.2%)
Total stent length 25.5 ± 13.5
De-novo lesions 539 (95.9%)
In-stent restenotic lesions 20 (3.6%)
Bifurcation 145 (25.8%)
Stents implanted per lesion 1.16 ± 0.47
Overlapping lesion 74 (13.4%)
BMI = body mass index; MI = myocardial infarction; CABG = coronary artery bypass
grafting; PCI = percutaneous coronary intervention.
Table 2






(cardiac death, MI, ciTVR)
15 (3.94%)
[2.39–6.47]
All death 6 (1.51%)
[0.68–3.34]
Cardiac death 3 (0.76%)
[0.25–2.33]
Myocardial infarction (MI) 4 (1.1%)
[0.41%2.95%]
Definite or probable stent thrombosis 1 (0.25%)
[0.04–1.77]
Target vessel revascularization (ciTVR) 10 (2.6%)
[1.41–4.79]
POCE (All death, MI, ciTVR) 18 (4.68%)
[2.97–7.34]
MACE = major adverse cardiac event; MI = myocardial infarction; ciTVR = clinically
indicated target vessel revascularization; POCE = patient orientated composite
endpoint.3. Results
3.1. Baseline patient and lesion characteristics
Baseline patient and lesion characteristics of the CoCr-BES reg-
istry population are shown in Table 1. As considered typical for an
all-comers population, the mean age was 64.7 years, 19% of
patients had diabetes, 21% were smokers, 57% had dyslipidaemia
and 57% had arterial hypertension. Over half of the patients pre-
sented with acute coronary syndromes (16.3% had ST segment ele-
vation MI (STEMI), 24.8% had non-ST-elevation MI (NSTEMI), and
14% presented with unstable angina). Patients had an average of
1.40 lesions for intervention with a balanced distribution of lesion
complexity; type B2 lesions in 25.6%, and type C in 26.7% of
patients. The average lesion length was 21.7 mm, the average ref-
erence vessel diameter (RVD) was 3.05 mm, 26.2% of patients had
small vessels treated with RVD < 2.75 mm, and the average total
stented length was 25.5mmm. Following stent implantation,
95.5% of the patients were discharged on DAPT and 68.8% were still
taking DAPT at 9 months.
3.2. Clinical outcomes at 9 months follow-up
Nine months clinical follow-up of the CoCr-BES registry popula-
tion was obtained in 97.8% of patients. The primary endpoint MACE
occurred in 15/400 patients (3.9%, 95% CI [2.39%-6.47%]). The inci-
dence of all cause death was 6/400 patients (1.5%), and cardiac
death occurred in 3/400 patients (0.8%). A total of 4/400 patients
(1.1%) experienced myocardial infarction. ARC definite or probable
stent thrombosis occurred in 1/400 of patients (0.25%), and 10/400
(2.6%) underwent clinically indicated target vessel revasculariza-
tion (ciTVR). The patient oriented composite endpoint (POCE)
occurred in 18/400 of patients (4.7%). Full details are shown in
Table 2.
3.3. Comparison with the LEADERS trial
A number of differences in the patient baseline characteristics
between the patients enrolled in the CoCr-BES registry versus the
LEADERS trial were noted. More patients in the registry presented
with renal failure (11.5% vs 5.3%), but fewer patients had hyperten-
sion (57.3% vs 72.5%), fewer patients had dyslipidaemia (56.7% vs
65,1%), fewer patients had previous MI (18.8% vs 33.2%) and fewer
patients had a history of previous PCI or CABG (24.6% vs 44.7%).
More details of patient characteristics are provided in Table S1.The outcomes of the conducted two-step comparison procedure
including propensity score and a day-3 landmark analysis are pro-
vided in Fig. 1c showing Kaplan-Meier curves of the primary
endpoint. The incidence of MACE was numerically lower for the
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vs 5.0%, HR 0.83; 95% CI [0.55–1.26], P = 0.38). Similarly, the inci-
dence of each of the MACE components, as shown in Table 3,
was numerically lower for the CoCr-BES. A trend towards a lower
incidence of clinically driven target vessel revascularization in
favour of the new CoCr Biomatrix AlphaTM stent was noted (ciTVR:
2.71% vs 4.24%, HR 0.63 95% CI [0.39 – 1.01], P = 0.056).
3.4. Comparison with previous studies and registries of the stainless
steel biolimus eluting stent
To help place the results of the CoCr-BES registry in context,
Table S3 in the supplementary material summarizes the key clin-
ical outcomes this registry together with those of the stainless steel
BES in the adjusted LEADERS arm, the SORT-OUT VI and SORT-OUT
VIII randomized trials, the e-Biomatrix, and the e-Biomatrix France
registries. While formal statistical analysis has not been under-
taken as time-points at which event rates were reported were dif-
ferent, outcomes from this CoCr-BES registry compare favourably
with those of the previous larger studies conducted with the stain-
less steel predecessor stent, particularly the low incidence of
repeat revascularization and low incidence of stent thrombosis
with the CoCr-BES.
4. Discussion
The key findings of the Biomatrix AlphaTM registry providing a
first real-life clinical experience with the new CoCr-BES are low
9-months rates of MACE (3.9%), myocardial infarction (1.1%), target
vessel revascularization (2.6%), and ARC definite or probable stent
thrombosis (0.25%). Such low event rates are in line with the find-
ings of contemporary studies of other latest generation DES [19]. In
a recently published randomized trial comparing the Zotarolimus-
eluting OnyxTM stent (Medtronic, Minneapolis, MN, USA) with the
Sirolimus-eluting OrsiroTM stent (Biotronik, Bülach, Switzerland),
the rates of target vessel failure were 4.5%, and 4.7%, respectively.
Accordingly, our findings support the efficacy and safety profile of
the new CoCr biolimus-eluting stent.
Given the absence of a control group, and with the aim of put-
ting these CoCr-BES outcomes into a wider clinical perspective, we
undertook a comparison with outcomes of the stainless steel BES
arm of the LEADERS trial. This comparison is of relevance as the
CoCr-BES registry was intentionally designed to be similar to the
LEADERS trial keeping a number of key protocol elements the same
including endpoints and follow-up duration. Further, a compre-
hensive statistical effort was made to make this comparison clini-
cally meaningful including propensity analysis and a landmark
analysis from day 3. While the incidence and time course of the
primary endpoint MACE (Fig. 1c) was similar, there was a trend
observed towards a lower incidence of repeat revascularization
with CoCr-BES (Table 3). The low rate of ARC definite/probable
stent thrombosis of 0.25% at 9 months in this all-comers cohort
is also noteworthy.Table 3
Propensity adjusted landmark analysis from day 3.
Clinical event Biomatrix AlphaTM Registry
(N = 397)
Primary endpoint at 9 months (MACE) 14 (4.29%)
Cardiac death 3 (0.72%)
Myocardial infarction 4 (1.28%)
ciTVR 9 (2.71%)
MACE = major adverse cardiac event, ciTVR = clinically indicated target vessel revasculaIt is reassuring that the CoCr-BES registry outcomes are similar
to the two previous randomized trials (SORT-OUT VI and SORT-
VIII) and two registries (e-Biomatrix Registry and the e-Biomatrix
France registry) conducted with the stainless steel BES, with
respect to cardiac death and MI, which is likely due the CoCr and
stainless steel stents sharing a similar stent design, the same drug,
the same drug dose, and the same biodegradable PLA polymer
(Table S3).
The reduction in strut thickness (CoCr-BES: 83um vs BES:
120um) is the most obvious change arising from the new CoCr-
BES design. Conceptually, this may lead to improvements in stent
deliverability with less associated vascular injury, and less intense
foreign body reaction of the vessel wall to the implant, which may
lead to more favourable healing. Almost two decades ago it was
suggested through the ISAR STEREO Trial with bare-metal stents
that a reduction in strut thickness may be associated with
improved clinical outcomes, namely a lower incidence of angio-
graphic restenosis as well as a lower repeat revascularization rate
[20]. More recently, a meta-analysis of 69 randomized drug-eluting
stent trials showed that patients receiving stents with ultra-thin
struts have lower rates of myocardial infarction and stent throm-
bosis [21]. The numerically lower repeat revascularization rate of
2.6% (ciTVR), and the low rate of stent thrombosis (0.25%) in our
registry could be related to reduction in strut thickness but they
could also be related to advances in procedural technique and con-
comitant drug therapy over the past decade, not fully adjusted for
in the propensity analysis. Overall, the favourable outcomes of our
CoCr-BES registry compared with historical control will likely be
interpreted as a manifestation of the benefits of thinner struts of
the CoCr-BES. However, while the improvements are certainly
within the expectations for a new CoCr thin strut stent design,
and while it might appear intuitive to assume better clinical out-
comes with thinner stent struts, we recommend interpreting the
data with caution, as to prove this concept, a randomized clinical
trial with the two stents only differing in the platform would be
needed.4.1. Study limitations
The major limitations of this registry are its relatively modest
sample size and the lack of a randomized control arm. As these reg-
istry data represent the first clinical evidence with the new CoCr-
BES, we sought to place the outcomes in clinically meaningful con-
text by undertaking a careful detailed comparison with historical
data derived from the stainless steel predecessor of the new stent,
including a propensity adjustment with the patients in the BES arm
that were not scheduled per protocol for angiographic follow-up,
and a landmark analysis from day 3 to compensate for a discrep-
ancy in the definition of peri-procedural MI. Despite these efforts,
it is possible that some baseline differences remain as confounding
factors.
In line with typical registry design elements, only 10% of the
patients in this registry were fully monitored, thus there is aBES (LEADERS)






32 (4.99%) 0.83 [0.55–1.26] 0.38
8 (1.23%) 0.60 [0.24–1.49] 0.27
10 (1.57%) 0.74 [0.34–1.59] 0.44
29 (4.24%) 0.63 [0.39–1.01] 0.056
rization.
6 I.B.A. Menown et al. / IJC Heart & Vasculature 26 (2020) 100472possibility of under-reporting of clinical events, although 100%
adjudication of MACE events was undertaken.
4.2. Conclusion
In this contemporary all-comers registry, the thin strut CoCr-
BES delivered safety and efficacy outcomes comparable to its pre-
decessor, the stainless steel BES. The low MACE rate of 3.9% at
9 months and the low 0.25% definite/probable stent thrombosis
rate are reassuring, in line with contemporary studies of other lat-
est generation DES, and support the clinical benefit of the new
biolimus-eluting stent technology incorporating a biodegradable
polymer, the BA-9 drug and a thin-strut CoCr stent platform.
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